Low-dose total body irradiation (LTBI) is used in the treatment of some cancers mainly for immune enhancement rather than cell killing. However, the mechanism underlying LTBI remains unknown. In this study, by analyzing the immune patterns of lymphocytes, we found that the percentage and absolute number of CD4 1 CD25 1 Foxp3 1 regulatory T cells are markedly decreased in naive mice following treatment with LTBI. On the contrary, the CD4 1 CD44 1 /CD8 1 CD44 1 effector-memory T cells are greatly increased. Importantly, naive mice treated with dendritic cell-gp100 tumor vaccines under LTBI induced an enhancement of antigen-specific proliferation and cytotoxicity as well as interferon-c (IFN-c) secretion against F10 melanoma tumor challenge, compared to treatment with either the tumor vaccine or LTBI alone. Consequently, the treatment resulted in a reduced tumor burden and prolonged mouse survival. Our data demonstrate that LTBI's enhancement of antitumor immunity was mainly associated with selectively decreasing the proportion and number of T regulatory cells, implying the potential application of the combination of LTBI and a tumor vaccine in antitumor therapy.
INTRODUCTION
Investigators have demonstrated that tumor-bearing mice exposed to low-dose total body irradiation (LTBI) experience an inhibition of tumor progression, which was not due primarily to the direct irradiated killing of tumor cells but rather to the effects of lymphopenia induced by irradiation. 1 A historical review by Berk and Hodes showed clearly that Roentgen therapy was used extensively and successfully for the treatment of many types of infections before the advent of antibiotics. 2 One of the theoretical bases of such treatment relies on the fact that low-dose irradiation makes host immune cells sensitive to antigen priming. 3, 4 Recent experiments explored the observation that irradiation-induced lymphopenia creates a huge space for lymphocyte activation and proliferation. 5 More importantly, those homeostatic proliferated cells acquire characteristics of memory and effector cells measured by phenotype and by hypersensitivity to antigen stimulation. Thus, lymphopenia setting may facilitate the induction of an immune response rather than immune tolerance. 6 Dendritic cells (DCs), the most powerful antigen-presenting cells, are widely used for antigen delivery in vaccine therapies against tumors. Many publications have shown that tumor lysate-pulsed DCs can elicit effective antitumor immune responses primarily in immunogenic tumor models. 7 Considering their poor immunogenicity, many tumor antigens (e.g., gp100), although delivered by DCs, fail to elicit effective antitumor immune responses. 8 Therefore, to elicit an antitumor immune response against poor immunogenicity tumor antigens, we hypothesize that the combination of LTBI and a DC-based vaccine may break the immunotolerance due to the enhancement of the better immune environment produced by LTBI. In this study, we investigated the capacity of DC-pulsed gp100, a melanoma-associated peptide, to elicit antitumor immunity in the setting of lymphopenia induced by 1.5 Gy LTBI. We found that immunization with DC-gp100 during early periods of lymphoid reconstitution primed an effective immune response against melanoma. Further study found that the selective reduction of CD4 1 CD25 1 Foxp3 1 T regulatory (Treg) cells during early lymphoid recovery after irradiation makes the microenvironment superior for antigen priming. Thus, DC-based immunotherapy, in combination with radiotherapy, can be used for treating tumors. Female C57BL/6 (H-2 b ) mice (Center of Experimental Animals, Shanghai, China), aged 8-12 weeks, were used in all experiments. All animals were housed under pathogen-free conditions. The F10 cell line (mouse melanoma cells) and 3LL cell line (mouse Lewis lung cancer cells) were kindly donated by Dr Hong-Ming Hu (EACRI, Portland, OR, USA). Tumor cell lines were cultured in RPMI 1640 medium (Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (Hycolone, Logan, UT, USA). The gp100 (KVPRNQDWL) peptide and MUT-1 octapeptide (FEQNTAQP) were custom-synthesized by Invitrogen Co. (Carlsbad, CA, USA).
MATERIALS AND METHODS

Mice and cell lines
Isolation and proliferation of bone marrow-derived DCs Primary DCs were obtained from mouse bone marrow precursors as described previously. 9 In brief, murine bone marrow cells were harvested from femurs and tibias and then plated in complete RPMI 1640 medium containing recombinant murine granulocyte-macrophage colony-stimulating factor (R&D Systems Inc., Minneapolis, MN, USA) and recombinant murine interleukin-4 (IL-4) (eBioscience Co., San Diego, CA, USA). On day 2, non-adherent granulocytes were gently removed, and loosely adherent cells were removed and replated. After 7-9 days of culturing, the maturation status and percentage of DCs were verified by flow cytometry, with three surface markers (CD11c, CD80 and class II antigen I-A b ) showing the purity of DCs to be greater than or equal to 75% and those DCs were predominantly maturated.
Animal irradiation and immunization C57BL/6 mice were irradiated with 1.25 Gy of gamma irradiation in a 137 Cs gamma irradiator. Eleven days after irradiation, two consecutive immunizations with 1310 6 gp100-loaded DCs were performed at 1-week intervals followed by inoculation with 1310 5 F10 cells. Tumor growth was monitored with calipers every other day and calculated as the product of maximal perpendicular diameters.
Long-term protection experiments
Surviving mice from several independent experiments that received the same treatment were pooled and rechallenged subcutaneously with 1310 5 live F10 cells. Naive mice, serving as controls, were also injected with the same number of tumor cells on the same day. Tumor growth was measured as described above.
Cell proliferation and cytokine-secretion detection One week after final immunization, spleen cells were harvested and cultured in vitro with gp100 peptide-loaded DCs in the presence of low-dose IL-2 for 3-10 days. [ 3 H] thymidine was added in the last 6 h. Proliferation was determined by [ 3 H]-thymidine uptake and expressed as the counts per minute. Supernatants from cells cocultured for 48 h were collected, and interferon-c (IFN-c) secretion was detected using an IFN-c enzyme-linked immunosorbent assay kit (eBioscience Co.).
In vitro cytotoxicity assay A flow-based killing assay was developed to measure cellular cytotoxicity of immunized splenocytes in vitro in a manner previously described. 10 In brief, cultured F10 cells, as well as the control 3LL cells, were collected and washed with phosphate-buffered saline, and then labeled with 5-and 6-carboxyfluorescein diacetate succinimidyl ester (Molecular Probes, Eugene, OR, USA). Labeling reactions were stopped with complete RPMI 1640 medium. Labeled target cells (1310 5 ) were added to 96-well V-bottom tissue culture-treated plates (Corning, New York, USA) along with indicated effector cells in complete RPMI medium containing recombinant human IL-2. The effector/target ratios were 80:1, 40:1 and 10:1. Before analysis, 7-aminoactinomycin D (Calbiochem, Los Angeles, CA, USA) was added to each sample. 7-aminoactinomycin D incorporation is used as a surrogate marker for late cell death/apoptosis.
Flow cytometry analysis
After restimulation with gp100 in vitro, splenocytes from immunized mice were first washed with phosphate-buffered saline and stained with anti-CD8, anti-CD4 or anti-CD44 antibody (BD Bioscience, San Jose, CA, USA). The antibody-bound splenocytes were then washed and resuspended in fluorescence-activated cell-sorting (FACS) buffer. 
FoxP3
1 Treg cell population, cells were first stained with anti-CD4 and CD25 antibodies, then fixed and permeabilized before they were stained with PE-Cy5-labeled anti-FoxP3 antibody (eBioscience Co.). After washing, cells were detected by FACSCalibor and analyzed with Cellquest software (BD Bioscience).
Statistical analysis
Data were presented as mean6SEM. Group differences were analyzed with one-way analysis of variance using Prism 5.0 software (GraphPad Software, San Diego, CA, USA), and P,0.05 was considered as a statistically significant difference.
RESULTS
Enhanced antitumor effects elicited by the DC-gp100 vaccine in LTBI To determine the effect of DC-gp100 vaccination under the treatment of LTBI, mice were irradiated by 1.25 Gy LTBI. Eleven days later, they were inoculated subcutaneously with DC-gp100 twice at 1-week intervals, and then challenged by 1310 5 F10 melanoma tumor cells. As shown in Figure 1a and b, mice that received either vaccination or Figure 1c ).
Induced lymphopenia-driven proliferation in mice under LTBI To elucidate why tumor vaccination under the treatment of LTBI protects mice from a tumor challenge, the dynamic change of lymphocytes was detected by FACS analysis. As shown in Figure 2 , the absolute cell number of lymphocytes was significantly decreased on day 4 in naive mice under the treatment of LTBI compared to any other groups (P,0.05), counted on blood (Figure 2a) , spleen ( Figure 2b ) and lymph nodes (Figure 2c ). Then, cell numbers recovered gradually and reached to the normal level by day 12, indicating that LTBI induced a lymphopenia-driven proliferation in a timedependent manner.
Enhanced gp100-specific antitumor immune response under LTBI To determine whether induced lymphopenia-driven proliferation under the LTBI treatment elicited an enhanced antigen-specific immune response against tumors, splenocytes from treated mice were tested for a gp100 antigen-specific immune response. Results showed that proliferative responses of the splenocytes from a DC-gp100 vaccine under pre-treatment with LTBI were greater than those splenocytes from either the DC-gp100 vaccine or the LTBI irradiation alone in response to gp100 peptide, but not to an irrelevant control peptide Mut-1 (P,0.05, Figure 3a) . Furthermore, splenocytes proliferated greatly when stimulated with parental inactivated F10 tumor cells, compared to irrelevant control 3LL tumor cells (P,0.05, Figure 3b ). This proliferation data strongly indicated that DCgp100 immunization pre-treated with LTBI-induced lymphocyte proliferation, and especially against F10-derived gp100 peptide and parental F10 tumor cells. A cytotoxicity assay showed that DC-gp100 immunization pre-treated with LTBI displayed a more potent and specific cytolytic killing activity against F10 target cells as compared to splenocytes derived from mice receiving DC-gp100 vaccination or mice receiving LTBI alone (P,0.05, Figure 3c ). In addition, primed splenocytes from combination-treated mice showed more IFN-c cytokine secretion compared to the controls (P,0.01), when splenocytes from DC-gp100 immunized mice with or without LTBI treatment were stimulated with either gp100 peptide (Figure 4a ) or inactivated F10 tumor cells in vitro (Figure 4b) Figure 3 Enhanced gp100-specific anti-tumor immune response under LTBI. Splenocytes from combination treated mice were stimulated with gp100 peptide in vitro. Cells were harvested and used to detect the specific proliferation for both gp100 peptide and irrelevant Mut-1 peptide (a) or for its parent tumor cells F10 and irrelevant tumor cells 3LL (b). The cytotoxic T lymphocyte (CTL) cytotoxicity was determined by double staining of CFSE and 7-AAD as described in the section on 'Materials and Methods'. Each of the curves represents the mean percentage of specific lysis of CTL induced by various treatments (c). Experiments were performed at least three times. *P,0.05, compared to any other group. 7-AAD, 7-aminoactinomycin D; CFSE, carboxyfluorescein diacetate succinimidyl ester; E:T ratio, effector/ target ratio; LTBI, low-dose total body irradiation. 
Foxp3
1 T cells is lower on day 10 or day 12 than on day 0 (P,0.01, Figure 5d ). On the contrary, the percentage of CD4
high effectormemory T cells were markedly increased in both spleen and lymph nodes, compared to day 0 (P,0.05, Figure 6a and b). These data strongly exhibited a changed immune pattern under the process of lymphopenia-driven proliferation pre-treated with LTBI, which tends to enhance the activation of effector T cells and to impair the suppressive function of Treg cells.
DISCUSSION
In this study, we examined the synergic antitumor effects of DC-gp100 vaccination and LTBI on a mouse melanoma model and showed that dendritic cell-pulsed peptide protects LTBI mice from tumor challenge. The heightened vaccine-based antitumor immune response in irradiated hosts was associated with tumor regression and prolonged survival of mice. It had previously been thought that some cytotoxic agents, such as cyclophosphamide, might enhance the efficacy of adoptively transferred immunotherapy by augmenting the engraftment of adoptively transferred tumor-reactive effector T cells, [11] [12] [13] possibly by creating space. 1, 14 However, in our study, vaccination after irradiation without adoptive transfer yielded similar results, indicating that a self-reconstituted host immune system is reliable for antigen stimulation.
Irradiation can destroy the immune system to some extent by decreasing peripheral lymphocytes. To maintain the immune homeostasis, remaining lymphocytes begin to divide and fill in the peripheral lymphocyte pool, termed lymphodepletion-driven cell proliferation, Figure 4 Enhanced IFN-c production induced by DC-gp100 vaccination under LTBI. Splenocytes from combination-treated mice were stimulated with gp100 peptide in vitro. The supernatant was harvested and used to detect IFN-c secretion for both gp100 peptide and irrelevant Mut-1 peptide (a) or for its parent tumor cells F10 and irrelevant tumor cells 3LL (b). Experiments were performed at least three times. **P,0.01, *P,0.05. DC, dendritic cell; IFN-c, interferon-c; LTBI, low-dose total body irradiation. 
Foxp3
1 Treg cells in LNs was determined by flow cytometry and counting the total number of cells (d). Experiments were performed at least three times. **P,0.01, compared to the untreated group. FACS, fluorescence-activated cell-sorting; LTBI, low-dose total body irradiation; Treg, T regulatory.
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and acquire many of the surface markers of effector-memory T cells (e.g., CD44
high and CD62L low ). 15, 16 Those divided effector-memory T cells possess similar functions of natural memory T cells and are reliable for priming when exposed to antigens. 17, 18 We propose that antigen stimulation during homeostatic proliferation will selectively expand antigen specific lymphocytes, which has been well characterized by others in adoptive transfer mouse models. 15, 16 We detected the kinetic changes of those effector-memory T cells and found that the proportion of CD44 high T cells increased in accordance with the recovery of cell numbers. However, the enhancement of effector-memorylike T cells is not sufficient for breaking immunotolerance to tumor weak antigens. In our study, we found that the contribution to the enhanced antitumor immunity is the diminished quantity of Treg cells after lymphodepletion treated with LTBI. As shown in the results, the proportion of CD4 1 CD25 1 Foxp3 1 Treg cells decreased after irradiation. Accordingly, splenocytes from irradiated mice proliferate more vigorously in the presence of anti-CD3 compared with those from non-irradiated counterparts (data not shown). Many publications have shown the regulatory role of CD4 1 CD25 1 Foxp3 1 Treg cells in suppressing immune responses to various antigens, including tumor-associated antigens in normal T-replete mice. 19, 20 Depletion or dysfunction of such cells in vivo is associated with the regression of established tumors or the occurrence of autoimmune disease. 21, 22 Our previous study showed that the chemotherapy drug paclitaxel selectively decreased the size of the Treg cell population rather than other subsets including effector T cells. Additionally, the inhibitory function of Treg cells was significantly impaired, whereas the production of Th1 cytokines, IFN-c and IL-2, was greatly augmented after paclitaxel treatment. 23 Based on the information above, and considering that radiotherapy has a similar function to chemotherapy, the data indicated that LTBI treatment may selectively reduce the population of CD4 1 CD25 1 Foxp3 1 Treg cells, and the effector T cells may proliferate faster.
It is generally believed that radiation in any amount will damage cells and the mutated cells could become cancerous. However, a large amount of research over the past century on the effects of low doses of ionizing radiation on biological organisms has shown the beneficial health effects of this intervention, called hormesis. 22, 24 Our findings support this notion by demonstrating that irradiation diminishes the number of Treg cells, a suppressive cell subset, yet the clear underlying mechanism remains controversial.
In summary, we have shown that a therapeutic, low dose of irradiation enhances the antitumor immunity induced by DC vaccination, a related mechanism involved in cytotoxic T-lymphocyte cytotoxicity and reduction of Treg cells. Our studies provide a strong experimental basis for novel clinical trials to determine whether the combination of DC-based tumor vaccination with LTBI applied in cancer patients would enhance tumor regression and improve survival. 1 or CD8 1 T cells, by flow cytometry every week. Experiments were performed at least three times. *P,0.05, compared to the untreated group. LN, lymph node; LTBI, low-dose total body irradiation.
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